Best confirmed chemical starting points

Our extensive early drug discovery experience is manifested through the highly efficient workflows in our projects, undeniably facilitating the delivery of the best confirmed chemical starting points for your drug discovery in various target classes and cellular phenotypes across numerous disease areas.

Disease Area



- 31% Oncology
- 15% Immunology and inflammation
- 14% Infectious diseases
- 7% Neglected diseases
- 12% Neurology & CNS
- 7% Cardiovascular diseases
- 4% Immunocology
- 4% Metabolic diseases
- 1% Genetic diseases
- 1% Obesity
- 1% Antimicrobial resistance
- 1% Airway diseases
- 2% Other

Target Class

- 53% Enzyme
- 17% Receptor
- 9% PPI
- 7% Phenotypic
- 6% Protein
- 3% Ion Channel
- 2% Antibody

Projects with clear milestones, deliverables and timelines

Pivot Park Screening Centre is a project-driven organization and as such is organized in a matrix structure, in which project teams are formed with internal members including a project leader, one to two assay development scientists, one to two automation scientists, an account manager, a project principal and external outsourcing members. After initiation of projects based on a mutually agreed upon work package with clear milestones, deliverables, acceptance criteria, and timelines, outsourced projects typically start with a kickoff meeting and scheduling biweekly or monthly online progress meetings. Upon kickoff, projects start with either the transfer of an existing assay cascade from our customers for further optimization and miniaturization, or the development of novel screening assay cascades from scratch and subsequent optimization and miniaturization to an uHTS ready format.



“Over the last decade, PPSC has demonstrated industry-leading capabilities and knowledge in developing tailored biochemical, cellular, and biophysical assay solutions to enable the discovery of high-quality novel chemical matter for a broad range of target classes through ultra-High Throughput Screening with exemplary efficiency and flexibility.
Our passionate scientists, pharma-grade screening infrastructure and strategic partnerships are the foundation of PPSC’s track record in accelerating drug discovery programs of our pharma and biotech clients.”

Saman Honarnejad, PhD
Chief Scientific Officer

How can we help you?

Are you looking for ways to accelerate your drug discovery?
Contact us to explore how we can improve global health together.

+31 (0) 412 846050 | info@ppscreeningcentre.com | ppscreeningcentre.com

pivotpark screeningcentre

pivotpark screeningcentre

We help you to accelerate drug discovery

PPSCREENINGCENTRE.COM

pivotpark screeningcentre

Are you looking for lead candidate compounds for your target or cellular phenotype, and do you want your drug discovery program to be more efficient, both in terms of time and cost?

We provide drug discovery services in the fields of biochemical, biophysical and cellular assay development, lab automation, ultra-High Throughput Screening or uHTS (usually in 1536-well format) and hit-to-lead biological profiling.

We tailor each project to your specific scientific and technical requirements to ensure rapid delivery of high-quality and tractable chemical starting points for lead discovery.

You can either bring your own compound library or use our 300K IP-free drug-like compound library. Our fully automated robotic system can generate up to 350,000 high-quality data-points per day and we can store up to 2.5 million small molecules for on-the-fly screening.

In fact, over the past 10 years we have successfully completed more than 200 full-deck screening campaigns and carried out 500 assay development projects for a broad range of target classes across many disease areas, using various assay types.

What makes us unique?

- Integrated approach for early drug discovery
- Rapid generation of high-quality hits; All major read-out modalities available in-house including FLIPR and Mass Spectrometry
- Specialists in miniaturizing your assay to 1536-well format
- Handling of large small molecule libraries; bring your own library or use our 300k in-house compound library
- State-of-the-art big pharma-like uHTS set-up coupled with top-notch read-out technologies
- Very experienced screening site for pharma-clients, charities and start-ups
- Broad knowledge in different label-free and label-based assay development-solutions including Affinity Selection Mass Spectrometry (ASMS)

The right assay for your target both within budget and your timelines

Our scientists have longstanding and proven experience in assay development for the most challenging targets. We believe each project has unique aspects, and we collaborate with you to deliver tailored and high-quality assays. We achieve this by first having a detailed scientific assessment of your project requirements. After that, we tailor a proposal ranging from a reliable screening cascade to a stand-alone assay to address your particular needs. No matter how challenging your target is, our scientists will ideate out-of-the-box solutions and propose the best fitting approach in order to develop the right assays suitable for target evaluation, ultra-High Throughput Screening, hit triaging and hit-to-lead biological profiling.

Label-based and label-free biochemical, cellular and biophysical assay development

We provide access to a wide range of label-based and label-free biochemical, cellular and biophysical assays, that are optimized to deliver high-quality and robust data. Our scientists have ample experience in a variety of readout technologies including the common label-based biochemical and cellular ones, as well as label-free MALDI-TOF mass spectrometry biochemical, affinity-based and cellular assays.

Your Assay tailor-made for ultra-High Throughput Screening by means of miniaturization

By means of miniaturization, we are able to reduce sample volumes and screen more compounds per plate, limiting compounds and reagents used as well as time, while maintaining reliability, robustness, and reproducibility. This makes the miniaturization of a screening assay an essential step to cost-effectively explore large chemical spaces for your drug discovery process.

96-, 384- or 1536-well format, giving you optimal flexibility during your drug discovery project

Bring your own library or use our 300.000 in-house IP-free small molecule library

Pivot Park Screening Centre not only has its own diversity-based library of over 300,000 high-quality drug-like compounds, but also offers ample flexibility to accommodate your own library or request specific vendor sets. We handle small molecule libraries of several millions of compounds per screen, allowing big pharma-grade uHTS operations. In other words, giving you the greatest coverage of chemical space to maximize the chance of finding tractable and diverse hit clusters and singletons.

Our wide range of assays based technologies:

- Fluorescence Intensity
- Absorption
- Fluorescence Polarization
- Time Resolved Fluorescence (FRET, TR FRET, HTRF)
- FLIPR
- Phenotypic
- Mass Spectrometry
- Affinity Selection Mass Spec
- High Content
- AlphaScreen®
- Luciferase
- Beta-lactamase
- BRET
- Aequorine
- Calcium Kinetics
- Calcium Permeability
- Membrane Potential
- Potassium Kinetics

Large-scale screening campaigns at low cost and in short timelines

By outsourcing your ultra-High Throughput Screening campaigns to our passionate team, you can benefit from our longstanding experience with the most challenging targets and assays, pharma-standard infrastructure and operations, all of which contribute to accelerating your lead discovery program.
At Pivot Park Screening Centre, we offer state-of-the-art and flexible automation for ultra-High Throughput Screening using a variety of assay types (biochemical, cellular, biophysical) in 96-, 384- or 1536-well plate format to find and optimize novel chemical starting points for drug discovery. Our industrial uHTS platform allows us to generate up to 350,000 high-quality data points per day.

Early assessment of target engagement with Affinity Selection Mass Spectrometry

Mass Spectrometry helps you to save time and cost of your drug discovery program

Mass Spectrometry (MS) is one of the read-out technologies integrated into our uHTS system. This technology can directly track the abundance of the molecule(s) of interest without the hassle of introducing labels and the risk of such labels interfering with other components in your assay.
Label-free assays can reduce the number of false positives and false negatives in your screen, making the hit-to-lead phase of your drug discovery program more time- and cost-effective. We can handle 1536-well plates and perform fully automated MS-based screening.

More samples in less time, while improving accuracy and reproducibility; easily transfer compounds with our automated liquid handling systems

The automation infrastructure at Pivot Park Screening Centre includes advanced automated liquid handling systems, which enable us to reduce timelines and deliver results faster. This gives our scientists more time to focus on the performance and the analysis of the data.

Receive qualified hit series

Our highly professional project teams facilitate hit prioritization by coupling the biochemical, cellular and biophysical data generated in projects, with in-depth medicinal chemistry knowledge and advanced cheminformatics tools to deliver the most promising and tractable hit series to clients.
We exploit various database- and text-mining tools to provide you with published *in-vitro/in-vivo* efficacy, selectivity and ADME-Tox data associated with the chemical space of your hit series to accelerate hit expansion and de-risk hit-to-lead efforts.

Hit series that can be quickly optimized to robust lead candidates and beyond.

In collaboration with our chemistry partners, we can provide a full hit-to-lead package including early *in-vitro* ADME-Tox profiling to develop high-quality lead candidates.